MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CARMEL, Ind., Sept. 16, 2024 ( GLOBE NEWSWIRE ) -- MBX Biosciences, Inc. ( Nasdaq: MBX ) ( "MBX Biosciences" ) , a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today ...
| Ticker |
Sentiment |
Impact |
|
BR
|
Neutral
|
6 %
|
|
MBX
|
Somewhat Bullish
|
76 %
|
